Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Aurobindo to buy Portuguese firm
by Jean-François Tremblay
January 23, 2017
| A version of this story appeared in
Volume 95, Issue 4
India’s Aurobindo Pharma will pay $144 million to acquire the Portuguese firm Generis Farmacêutica. Both companies produce generic drugs, but Aurobindo is also back-integrated into the production of active pharmaceutical ingredients. Aurobindo expects the purchase will make it the largest supplier of generic drugs in Portugal. It plans to use the output of Generis’s plant to supply Portugal as well as other countries in Europe. Currently owned by the private equity firm Magnum Capital Partners, Generis recorded sales of $70 million last year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter